CytomX Therapeutics’ (CTMX) neutral rating was reaffirmed at HC Wainwright

HC Wainwright reaffirmed its neutral rating on the stock CytomX Therapeutics (NASDAQ:CTMX – Free Report) in a report published Thursday morning, reports Benzinga.

Several other research analysts have recently issued reports on CTMX. Piper Sandler raised CytomX Therapeutics from a neutral rating to an overweight rating and lifted their price target for the stock from $2.25 to $3.50 in a research note on Tuesday, May 28th. StockNews.com cut shares of CytomX Therapeutics from a buy rating to a hold rating in a research report on Monday, June 17th. BMO Capital Markets lifted their price objective on CytomX Therapeutics from $3.25 to $3.59 and gave the stock a market perform rating in a research report on Thursday, May 9th. Jefferies Financial Group upgraded CytomX Therapeutics from a hold rating to a buy rating and upped their target price for the company from $2.50 to $8.00 in a report on Monday, May 6th. Finally, Wedbush raised CytomX Therapeutics from a neutral rating to an outperform rating and boosted their price target for the stock from $3.00 to $8.00 in a report on Thursday, May 9th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of Hold and an average price target of $5.77.

Read our latest research report on CytomX Therapeutics

CytomX Therapeutics trading down 6.3%

CTMX stock opened at $1.19 on Thursday. The company’s 50-day moving average price is $1.31 and its 200-day moving average price is $1.80. CytomX Therapeutics has a 52-week low of $1.04 and a 52-week high of $5.85. The company has a market cap of $92.72 million, a P/E ratio of 5.95 and a beta of 1.06.

CytomX Therapeutics (NASDAQ:CTMX – Get Your Free Report ) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). CytomX Therapeutics had a negative return on equity of 30.70% and a net margin of 13.87%. The firm had revenue of $25.12 million for the quarter, compared to analysts’ expectations of $21.79 million. During the same period last year, the firm earned ($0.02) EPS. On average, equities research analysts expect that CytomX Therapeutics will post -0.14 earnings per share for the current year.

Institutional investors are weighing in on CytomX Therapeutics

Several hedge funds have recently made changes to their positions in CTMX. Forefront Analytics LLC raised its position in CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after buying an additional 43,176 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in shares of CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 40,309 shares during the period. Sei Investments Co. purchased a new stake in shares of CytomX Therapeutics in the second quarter valued at approximately $467,000. XTX Topco Ltd boosted its holdings in CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 48,033 shares during the period. Finally, Acadian Asset Management LLC grew its position in CytomX Therapeutics by 1.4% during the second quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock worth $3,324,000 after buying an additional 37,739 shares during the last quarter. Institutional investors and hedge funds own 67.77% of the company’s shares.

CytomX Therapeutics Company Profile

(Get a free report)

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, is focused on the development of novel conditionally activated biologics localized to the tumor microenvironment. The company uses the conditional activation platform technology for research and development of oncology biologics, including validation of targets for antibody-drug conjugates (ADCs), opening the therapeutic window for new T-cell recruiters (TCEs) targeting solid tumors, and increasing the therapeutic index for the system immune. modulators, such as cytokines; and the PROBODY platform in preclinical research in areas outside of oncology.

Read more

Receive daily CytomX Therapeutics news and reviews – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CytomX Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.